OKYONasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

OKYO Pharma Ltd

OKYO Pharma Ltd is a U.S.-listed clinical-stage biopharmaceutical company focused on developing investigational therapies for neuropathic corneal pain and other anterior segment eye diseases. The company operates through drug development programs centered on urcosimod and related ophthalmology assets, with its ordinary shares listed on Nasdaq.

Ask about the company

Business

Share of revenue
Neuropathic corneal pain therapies100 %

Clinical-stage drug candidates intended to treat NCP, a chronic ocular pain condition.

Anterior segment eye disease therapies0 %

Investigational ophthalmic therapies aimed at diseases affecting the front part of the eye.

Clinical development services0 %

Internal R&D, trial planning, and regulatory development work for pipeline assets.

Customers

OKYO Pharma does not yet sell commercial products; its primary stakeholders are patients, ophthalmologists, and clinical investigators involved in its development programs. In a future commercialization scenario, the relevant customers would be physicians, specialty eye-care providers, and healthcare payers using approved ophthalmic therapies. For now, the company’s work is directed toward generating clinical evidence that supports eventual regulatory approval and physician adoption.

Clinical trial patients with NCP

Patients participating in studies of urcosimod and other investigational eye therapies.

Ophthalmology investigators and trial sites

Specialist physicians and clinical sites that recruit patients and generate trial data.

Regulatory authorities

Agencies reviewing safety and efficacy data needed for advancement to approval.

Future ophthalmology prescribers

Eye specialists who could prescribe approved treatments if development succeeds.

Strategy

OKYO Pharma’s core strategy is to advance urcosimod through late-stage clinical development for neuropathic corneal pain and build evidence for potential registration. The company is also strengthening its ophthalmology-focused leadership and maintaining access to capital so it can execute longer-duration clinical programs. Its commercial value depends on generating differentiated clinical data in a niche eye-disease category with limited approved treatment options.

Complete Phase 3 development of urcosimodShort term

Late-stage data are the main value-creation step for a clinical-stage biotech.

Strengthen ophthalmology pipeline positioningMedium term

A focused eye-disease portfolio can support follow-on development beyond the lead program.

Preserve funding for development executionShort term

Clinical trials and regulatory work require ongoing capital before any product revenue exists.

Geography

OKYO Pharma is headquartered in London and operates as a foreign private issuer listed in the United States on Nasdaq. Its development activities are organized around global clinical trial execution, with the company explicitly planning a global Phase 3 study for urcosimod. As a clinical-stage biotech, its geography matters mainly through trial-site selection, regulatory pathways, and access to capital markets rather than manufacturing footprint.

Risks

OKYO Pharma is exposed to the usual clinical-stage biotech risks: trial failure, safety or efficacy concerns, regulatory delays, and the possibility that a lead asset never reaches commercialization. Because it has no marketed products, its value is also highly dependent on external financing and on the ability to generate positive clinical data in a narrow ophthalmology indication.

Sorted by severity
LowMediumHighLowMediumHighImpact →Likelihood →Late-stage clinical failure1Regulatory approval delay or denial3Dilution from future capital raises2Reimbursement and pricing pressure4
Impact is the risk’s severity and likelihood how probable it is over the next few years, both assessed from the company’s reports. Numbers match the list.
  1. Late-stage clinical failureImpact: CriticalLikelihood: Medium

    The company’s value depends on positive Phase 3 data for urcosimod.

    Exposure: Lead NCP program

  2. Dilution from future capital raisesImpact: HighLikelihood: High

    Clinical-stage companies typically fund operations through equity issuance.

    Exposure: Ongoing R&D and G&A funding

  3. Regulatory approval delay or denialImpact: HighLikelihood: Medium

    Even successful trials require regulator acceptance of the evidence package.

    Exposure: Global Phase 3 and registration pathway

  4. Reimbursement and pricing pressureImpact: MediumLikelihood: Medium

    Even approved ophthalmic drugs can face coverage limits and cost controls.

    Exposure: Future commercial launch

Ask Clarifo about OKYO Pharma Ltd

Accounting

Judgemental items
Research and development expense

Clinical trial spend is expensed as incurred and drives reported losses.

Impact: Directly affects operating loss and comparability between periods

General and administrative expense

Public-company reporting, legal, audit, and investor relations costs are meaningful for a small biotech.

Impact: Can increase as headcount and compliance needs grow

Equity financing and dilution

Capital raises are central to funding the pipeline and change share count economics.

Impact: Affects per-share analysis and ownership dilution

UK R&D tax relief

The company notes eligibility for tax cash credits tied to surrenderable losses.

Impact: Can offset cash burn and influence tax line items

Similar listed companies

Publicly listed companies with a comparable business focus.

Ocean Biomedical, Inc.

OCEA · Pharmaceutical Preparations

Oculis Holding AG

OCS · Pharmaceutical Preparations

Kiora Pharmaceuticals, Inc

KPHMW · Pharmaceutical Preparations

EyePoint, Inc.

EYPT · Laboratory Analytical Instruments

Ocugen, Inc.

OCGN · Biological Products, (No Diagnostic Substances)

Vicore Pharma Holding AB

VCRE · Pharmaceutical Preparations

Last updated: 28/09/2026